Singular Genomics Systems Inc (OMIC) Cotización

Buyout from Deerfield now is 24.

Buyout was at $12 and at $20 now

Singular Genomics Receives Non-Binding Acquisition Proposal from Deerfield

&8.28 +’50%

Let’s go low floater

OMIC 5.78 - getting clobbered down to approximately 1/8-of-cash. WOW, never seen a stock's Price/Cash ratio fall this low...I guess mr market truly believes that OMIC management will just piss off the remaining pile of IPO cash...no closing-up-shop for an easy 5-bagger, no big sales, no orchestrated pump, not even a dead cat bounce??

Post R/S, OMIC now qualifies as a low-floater with only 2.5M O/S...I've been slowly adding in this temporary nosedive...

https://capedge.com/company/1850906/OMIC

OMIC new 52 week low

OMIC 10Q due 3/18

Easy $ tomorrow...

Short boys. Ihub top contrerian has spoken.

OMIC NEXT BIO POPADOPPER

OMIC new 52 week low

OMIC new 52 week low

OMIC new 52 week low

OMIC new 52 weewk low

OMIC new 52 week low

Fill the gaps at 3.24 and 3.00

Gaps 3.00, 3.24, 3.64

Gap at 3.00

“4:30p ET 5/10/2022 - Benzinga
Singular Genomics Collaborates With NVIDIA To Deliver Market-Leading Next-Generation Sequencing And Analysis Speeds

Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the company is collaborating with NVIDIA to validate and optimize the performance of the G4 Sequencing Platform with NVIDIA Clara Parabricks for secondary analysis including alignment and variant calling with over 50 tools for germline and somatic workflows.

This collaboration will enable access to Clara Parabricks for researchers and clinicians using Singular's G4 next-generation instrument, enabling users to run accelerated bioinformatics pipelines for key applications, such as whole genome sequencing, exome sequencing, RNA sequencing (RNA-Seq), and targeted gene panels. This solution will be seamlessly available to customers through Amazon Web Services Cloud implementation or on-premises servers that have NVIDIA GPUs.

"We are thrilled to bring NVIDIA's powerful analytical genomics workflows to Singular Genomics customers as a plug-and-play solution," said Jorge Velarde, Senior Vice President of Corporate Development and Strategy at Singular Genomics. "This collaboration further strengthens our industry-leading speed, providing researchers and clinicians with an opportunity to achieve significantly faster time to results. We look forward to working with NVIDIA and plan to disclose new data in the coming months that demonstrates the optimized performance through these platforms."

NVIDIA technology is used throughout genomics to accelerate traditional and deep learning analytics both within and off instrument for primary, secondary and tertiary genomic analysis. The G4 Sequencing Platform utilizes the NVIDIA RTX A6000 for AI-enabled basecalling. This announcement extends the collaboration to downstream workflows.

"Time to results is crucial across most NGS applications, and we believe that Clara Parabricks and NVIDIA's best-in-class GPU architecture combined with the speed and flexibility of the G4 Sequencing Platform is a natural fit," said George Vacek, Global Director of Genomics Alliances at NVIDIA. "The solution will be impactful to the genomics community and contribute to the advancement of science and medicine."

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”

Today: “Singular Genomics' management is scheduled to participate in a fireside chat Tuesday, June 14, 2022, at 4:00 p.m. Pacific Time / 7:00 p.m. Eastern Time. Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation on the News & Events section of the company's investor relations website at https://investor.singulargenomics.com/news-events/event-calendar.”

Reversal to trend higher around 12:30 today

“11:29a ET 5/11/2022 - Dow Jones
Singular Genomics Systems Is Maintained at Buy by Goldman Sachs”

“Cash, cash equivalents and short-term investments, excluding restricted cash, as of March 31, 2022 totaled 316.0 million.”

Outstanding shares: 70 million

316/70 = $4.51 per share with no multiple added and no value placed on the companies products, just based on cash owned by the company this stock is currently undervalued by almost a $1.50 today. Absolutely incredible.

Follow the cup and handle pattern back to 6.00 a share.